↓ Skip to main content

Cancer drugs in 16 European countries, Australia, and New Zealand: a cross-country price comparison study

Overview of attention for article published in Lancet Oncology, January 2016
Altmetric Badge
273

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (99th percentile)
  • High Attention Score compared to outputs of the same age and source (98th percentile)

Mentioned by

news
24 news outlets
blogs
2 blogs
twitter
118 tweeters
facebook
6 Facebook pages

Citations

dimensions_citation
83 Dimensions

Readers on

mendeley
173 Mendeley
citeulike
1 CiteULike
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Cancer drugs in 16 European countries, Australia, and New Zealand: a cross-country price comparison study
Published in
Lancet Oncology, January 2016
DOI 10.1016/s1470-2045(15)00449-0
Pubmed ID
Authors

Sabine Vogler, Agnes Vitry, Zaheer-Ud-Din Babar

Abstract

Cancer drugs challenge health-care systems because of their high prices. No cross-country price comparison of cancer drugs for a large number of countries has been published. We aimed to survey the prices of cancer drugs in high-income countries (Europe, Australia, and New Zealand). Based on comparability in terms of the economic situation and of the pharmaceutical system, we surveyed official list prices per unit at ex-factory price level of 31 originator cancer drugs in 16 European countries, Australia, and New Zealand as of June, 2013. Drug price data for the European countries were provided by the Pharma Price Information (PPI) service; Australian and New Zealand drug price data were retrieved from the respective pharmaceutical schedules. In Austria, Denmark, Finland, Germany, Italy, Norway, Sweden, and the UK, price information was available for all or all but one drug surveyed whereas the availability of price data was restricted for some drugs in other countries, especially in New Zealand and Portugal. The difference of a drug price between the highest priced country and the lowest priced country varied between 28% and 388%. A few drugs had lower outliers, especially Greek and UK prices, and upper outliers (particularly prices in Switzerland, Germany, and Sweden). Overall, Greek prices ranked at a low level, whereas Sweden, Switzerland, and Germany showed price data in similarly high ranges. Our results showed variations in ex-factory prices of originator cancer drugs in the 18 surveyed countries. However, the surveyed prices do not include discounts negotiated by funding organisations because these discounts are confidential. Because pricing authorities can also only use these official undiscounted prices when they set prices through the common policy of external price referencing, they risk overpaying. Our findings provide an evidence base for policy makers to decide whether further policy measures related to drug prices are needed. None.

Twitter Demographics

The data shown below were collected from the profiles of 118 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 173 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United Kingdom 3 2%
Ecuador 1 <1%
Germany 1 <1%
Austria 1 <1%
Portugal 1 <1%
Spain 1 <1%
Unknown 165 95%

Demographic breakdown

Readers by professional status Count As %
Researcher 36 21%
Student > Master 32 18%
Other 25 14%
Student > Ph. D. Student 22 13%
Student > Bachelor 14 8%
Other 25 14%
Unknown 19 11%
Readers by discipline Count As %
Medicine and Dentistry 50 29%
Pharmacology, Toxicology and Pharmaceutical Science 21 12%
Economics, Econometrics and Finance 12 7%
Biochemistry, Genetics and Molecular Biology 10 6%
Social Sciences 10 6%
Other 37 21%
Unknown 33 19%

Attention Score in Context

This research output has an Altmetric Attention Score of 273. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 19 January 2017.
All research outputs
#46,651
of 13,907,701 outputs
Outputs from Lancet Oncology
#67
of 4,956 outputs
Outputs of similar age
#1,513
of 359,380 outputs
Outputs of similar age from Lancet Oncology
#2
of 141 outputs
Altmetric has tracked 13,907,701 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 99th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 4,956 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 24.2. This one has done particularly well, scoring higher than 98% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 359,380 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 99% of its contemporaries.
We're also able to compare this research output to 141 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 98% of its contemporaries.